Flu-like symptoms and associated immunological response following therapy with botulinum toxins

Neurotoxicity Research

Volumn 24, Issue 2, 2013, Pages 298-306

  Baizabal Carvallo, José Fidel ^a   Jankovic, Joseph ^a   Feld, Jordan ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Botulinum toxins; Cytokines; Dystonia; Immune response; Inducible protein 10; Side effects

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; AGE DISTRIBUTION; ANOREXIA; ARTHRALGIA; ARTICLE; BLEPHAROSPASM; CERVICAL DYSTONIA; CHILL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; CRANIOCERVICAL DYSTONIA; DISEASE SEVERITY; DRUG FEVER; DRUG INDUCED HEADACHE; DYSAUTONOMIA; DYSPNEA; DYSTONIA; FACIAL DYSTONIA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEMIFACIAL SPASM; HUMAN; IMMUNE RESPONSE; INTERVIEW; LIMB DYSTONIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RHINORRHEA; RISK FACTOR; SEX DIFFERENCE; SHIVERING; SIDE EFFECT; SNEEZING; SORE THROAT; SYSTEMIC DISEASE; TREMOR; WEAKNESS;

AGED; BOTULINUM TOXINS; COHORT STUDIES; DATA COLLECTION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84879794430     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-013-9400-9     Document Type: Article

References (20)

1. Baizabal-Carvallo JF, Jankovic J, Pappert E (2011) Flu-like symptoms following botulinum toxin therapy. Toxicon 58:1-7
2. Baizabal-Carvallo JF, Suresh K, Hunter C, Jankovic J (2012) Flu-like and systemic symptoms following treatment with botulinum toxins. Neurology 78(suppl 1):P01.230
3. Buttmann M, Merzyn C, Hofstetter HH, Rieckmann P (2007) TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol 190:170-176
4. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM (2005) Botulinum toxin type A injections: adverse events reported to the US Food and drug administration in therapeutic and cosmetic cases. J Am Acad Dermatol 53:407-415
5. Deeva I, Mariani S, De Luca C et al (2010) Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine 49:163-170
6. Eisele KH, Fink K, Vey M, Taylor HV (2011) Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 57:555-565
7. Elkins R (2005) Ambient analyte assay. In: Wild D (ed) The immunoassay handbook, 3rd edn. Elsevier, San Diego, CA, pp 48-61
8. Goebeler M, Trautmann A, Voss A, Bröcker EV, Toksoy A, Gillitzer R (2001) Differential and sequential expression of multiple chemokines during elicitation of allergic contact hypersensitivity. Am J Pathol 158:431-440
9. Jankovic J (2004) Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 75:951-957
10. Jankovic J (2009) Disease-oriented approach to botulinum toxin use. Toxicon 54:614-623
11. Kelley M, DeSilva B (2007) Key elements of bioanalytical method validation for macromolecules. AAPS J 9:E156-E163
12. Kukreja R, Chang TW, Cai S et al (2009) Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon 53:616-624
13. Lee JC, Yokota K, Arimitsu H et al (2005) Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostrdium botulinum type B 16S toxin-haemagglutinin. Microbiology 151:3739-3747
14. Moses H, Brandes DW (2008) Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. Curr Med Res Opin 24:2679-2690
15. Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20:981-990
16. Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ (2011) Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol 240-241:121-128
17. Samineni S, Parvataneni S, Kelly C, Gangur V, Karmaus W, Brooks K (2006) Optimization, comparison, and application of colorimetric vs. chemiluminescence based indirect sandwich ELISA for measurement of human IL-23. J Immunoassay Immunochem 27:183-193
18. Sharma SK, Fu FN, Singh BR (1999) Molecular properties of a hemagglutinin purified from type A Clostridium botulinum. J Protein Chem 18:29-38
19. Thenganatt MA, Fahn S (2012) Botulinum toxin for the treatment of movement disorders. Curr Neurol Neurosci Rep 12:399-409
20. Viswanathan CT, Bansai S, Booth B et al (2007) Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res 24:1962-1973